Stanford scientists have developed species cross-reactive B7H3-targeting CAR-T cells that can effectively target both human and mouse tumors, enabling more accurate preclinical testing in immunocompetent models.
Stanford scientists have developed cross-reactive antibodies that can bind human and murine NKp46 on NK cells and induce cytotoxicity and proliferation.